SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: betty moyers who wrote (20152)3/28/1999 12:52:00 PM
From: VLAD  Read Replies (2) | Respond to of 23519
 
betty,

Looks to me like the smart shorts got out during the last big pop and the dumb shorts jumped in. Its not a good time to be short this stock and with 6 million plus shares still held short on a 29 million share float any good news going out is just going to make things tougher to cover. I expect a slow upward drift as institutions now accumulate and some shorts capitulate. With no big news breaking I expect a trading range of 3 1/2 to 4 1/2. A Japan announcement should allow us a pop breaking the upper resistance level at 6--maybe we go to 8 and then pull back to the 6 to 7 range. The real potential squeeze will come within the next 2 months when Vivus announces a domestic partner (with A/Z of course). If we are trading at 6 to 8 at that time and depending on the short interest still held, expect a squeeze that can create at least a double if not a triple to fill the 12/97 gap down.

My current price target with a Japan deal followed by a domestic partner deal is at least 15 and maybe 21. The time frame for this is to occur no longer than the end of Q2 (for the domestic partner) but expect the Japan announcement very soon.

Also, I know for a fact that Vivus has aquired technology for a new drug. I don't know what the drug is for but it is something totally new that we have never heard anything about.

We may even be so lucky as to get Spain approved before the end of this quarter but I don't expect it until Q2.